State Street Corp Sells 263,431 Shares of IQVIA Holdings Inc. (NYSE:IQV)

State Street Corp decreased its stake in shares of IQVIA Holdings Inc. (NYSE:IQV - Free Report) by 3.3% during the third quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 7,764,688 shares of the medical research company's stock after selling 263,431 shares during the period. State Street Corp owned about 4.28% of IQVIA worth $1,839,998,000 at the end of the most recent reporting period.

Several other institutional investors and hedge funds also recently added to or reduced their stakes in the stock. Quantinno Capital Management LP grew its stake in shares of IQVIA by 82.0% during the 3rd quarter. Quantinno Capital Management LP now owns 18,059 shares of the medical research company's stock valued at $4,280,000 after purchasing an additional 8,138 shares during the period. Point72 DIFC Ltd boosted its holdings in shares of IQVIA by 199.5% in the third quarter. Point72 DIFC Ltd now owns 2,289 shares of the medical research company's stock worth $542,000 after buying an additional 4,589 shares during the last quarter. Investment Management Corp of Ontario increased its holdings in IQVIA by 49.4% during the third quarter. Investment Management Corp of Ontario now owns 6,049 shares of the medical research company's stock valued at $1,433,000 after buying an additional 2,000 shares during the last quarter. HighTower Advisors LLC raised its position in IQVIA by 6.3% in the third quarter. HighTower Advisors LLC now owns 142,031 shares of the medical research company's stock worth $33,640,000 after acquiring an additional 8,436 shares during the period. Finally, Hilltop Holdings Inc. purchased a new position in shares of IQVIA during the 3rd quarter worth $446,000. Hedge funds and other institutional investors own 89.62% of the company's stock.

IQVIA Price Performance

Shares of IQV traded up $2.70 during mid-day trading on Friday, hitting $202.63. 1,388,125 shares of the stock were exchanged, compared to its average volume of 2,002,141. The firm has a 50-day moving average of $215.18 and a two-hundred day moving average of $225.11. IQVIA Holdings Inc. has a 52-week low of $187.62 and a 52-week high of $261.73. The company has a debt-to-equity ratio of 1.76, a quick ratio of 0.81 and a current ratio of 0.81. The company has a market cap of $36.78 billion, a PE ratio of 26.59, a price-to-earnings-growth ratio of 2.09 and a beta of 1.49.

Analyst Ratings Changes

Several research firms have recently commented on IQV. Morgan Stanley reduced their price objective on IQVIA from $280.00 to $265.00 and set an "overweight" rating for the company in a research note on Monday, November 4th. StockNews.com downgraded IQVIA from a "buy" rating to a "hold" rating in a research note on Thursday, November 28th. Redburn Atlantic assumed coverage on IQVIA in a research note on Monday, October 14th. They set a "buy" rating and a $276.00 price objective for the company. Evercore ISI decreased their target price on shares of IQVIA from $270.00 to $265.00 and set an "outperform" rating on the stock in a research note on Tuesday, October 8th. Finally, Royal Bank of Canada reissued an "outperform" rating and issued a $270.00 price objective on shares of IQVIA in a research note on Wednesday. Five investment analysts have rated the stock with a hold rating, fourteen have given a buy rating and one has given a strong buy rating to the stock. Based on data from MarketBeat.com, the company presently has an average rating of "Moderate Buy" and an average price target of $256.50.

About IQVIA

IQVIA Holdings Inc engages in the provision of advanced analytics, technology solutions, and clinical research services to the life sciences industry in the Americas, Europe, Africa, and the Asia-Pacific. It operates through three segments: Technology & Analytics Solutions, Research & Development Solutions, and Contract Sales & Medical Solutions.